Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1 clinical trials · Condition
◉ Watch Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
| Record | Firm | Date |
|---|---|---|
| Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (NCT03244956) | Gustave Roussy, Cancer Campus, Grand Paris | 2017-12-27 |
Track Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation automatically
Every clearance here is in the API, with alerts when new ones post.